Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 07 2021
Historique:
received: 11 02 2021
revised: 15 04 2021
accepted: 19 04 2021
pubmed: 26 4 2021
medline: 3 11 2021
entrez: 25 4 2021
Statut: ppublish

Résumé

Cyclin-dependent kinase 9 (CDK9) is a member of the cyclin-dependent kinase (CDK) family which is involved in transcriptional regulation of several genes, including the oncogene Myc, and is a validated target for pancreatic cancer. Here we report the development of an aminopyrazole based proteolysis targeting chimera (PROTAC 2) that selectively degrades CDK9 (DC

Identifiants

pubmed: 33895280
pii: S0960-894X(21)00287-0
doi: 10.1016/j.bmcl.2021.128061
pmc: PMC8187316
mid: NIHMS1697804
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Bridged Bicyclo Compounds, Heterocyclic 0
Protein Kinase Inhibitors 0
Pyrazoles 0
Sulfonamides 0
CDK9 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 9 EC 2.7.11.22
venetoclax N54AIC43PW

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

128061

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM121316
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA036727
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197999
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA251151
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

J Med Chem. 2004 Jun 17;47(13):3367-80
pubmed: 15189033
Leuk Res. 2011 Jun;35(6):821-30
pubmed: 21216463
Chem Commun (Camb). 2017 Jul 4;53(54):7577-7580
pubmed: 28636052
Cell Cycle. 2011 Jan 1;10(1):28-32
pubmed: 21200140
Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3736-3740
pubmed: 30343954
Bioorg Med Chem Lett. 2019 Jun 1;29(11):1375-1379
pubmed: 30935795
Oncogene. 1999 Aug 12;18(32):4598-605
pubmed: 10467404
Cancer Res. 2008 May 1;68(9):3421-8
pubmed: 18451170
Curr Med Chem. 2017;24(40):4488-4514
pubmed: 28901269
J Biol Chem. 2010 May 14;285(20):15016-15026
pubmed: 20223826
Cancer Cell. 2006 Nov;10(5):375-88
pubmed: 17097560
Mol Pharmacol. 2019 Oct;96(4):419-429
pubmed: 31467029
Clin Cancer Res. 2011 Sep 15;17(18):5973-81
pubmed: 21821698
EMBO Rep. 2010 Nov;11(11):876-82
pubmed: 20930849
Science. 2015 Jun 19;348(6241):1376-81
pubmed: 25999370
Nat Biotechnol. 2011 Oct 30;29(11):1039-45
pubmed: 22037377
Cancers (Basel). 2015 Jan 23;7(1):179-237
pubmed: 25625291
Cancer Res. 2005 Jun 15;65(12):5399-407
pubmed: 15958589
J Med Chem. 2016 Oct 13;59(19):8667-8684
pubmed: 27171036
J Med Chem. 2019 Aug 22;62(16):7575-7582
pubmed: 31330105
BMC Cancer. 2012 Nov 21;12:541
pubmed: 23171055
Sci Signal. 2019 Jul 16;12(590):
pubmed: 31311847
Chembiochem. 2007 Nov 23;8(17):2058-62
pubmed: 17907127
Oncotarget. 2017 Dec 28;9(4):5216-5232
pubmed: 29435174
Bioorg Med Chem. 2012 Apr 1;20(7):2227-34
pubmed: 22386982
Chem Biol Drug Des. 2020 Aug;96(2):773-784
pubmed: 32237047
Open Biol. 2018 Sep;8(9):
pubmed: 30185601
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9
pubmed: 11438690
Nat Chem Biol. 2018 Feb;14(2):163-170
pubmed: 29251720
ACS Chem Biol. 2015 Aug 21;10(8):1770-7
pubmed: 26035625
Bioorg Chem. 2018 Dec;81:373-381
pubmed: 30196207
ACS Chem Biol. 2018 May 18;13(5):1148-1152
pubmed: 29608269
Genes Dev. 2014 Aug 15;28(16):1800-14
pubmed: 25128497
Cell Chem Biol. 2019 Feb 21;26(2):300-306.e9
pubmed: 30595531
Eur J Med Chem. 2021 Feb 5;211:113091
pubmed: 33338869
Chem Biol. 2015 Jun 18;22(6):755-63
pubmed: 26051217

Auteurs

Hannah M King (HM)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Sandeep Rana (S)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Sydney P Kubica (SP)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Jayapal Reddy Mallareddy (JR)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Smitha Kizhake (S)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Edward L Ezell (EL)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Muhammad Zahid (M)

Department of Environmental, Agricultural and Occupational Health, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Michael J Naldrett (MJ)

Proteomics & Metabolomics Facility, Nebraska Center for Biotechnology, University of Nebraska, Lincoln, NE 68588, USA.

Sophie Alvarez (S)

Proteomics & Metabolomics Facility, Nebraska Center for Biotechnology, University of Nebraska, Lincoln, NE 68588, USA.

Henry C-H Law (HC)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Nicholas T Woods (NT)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68022, USA.

Amarnath Natarajan (A)

Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68022, USA; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68022, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68022, USA. Electronic address: anatarajan@unmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH